MIRATI.COM: Keyword Density Checker

Total words: 2780 | 2-word phrases: 726 | 3-word phrases: 784 | 4-word phrases: 803

PAGE INFO

Title	Try to keep the title under 60 characters (78 characters) Mirati Therapeutics, Inc. \| Relentless Focus on Innovation \| Targeted Oncology
Description	Try to keep the meta description between 50 - 160 characters (143 characters) At Mirati, we are relentlessly focused on developing best-in-class targeted therapies to meaningfully impact the lives of patients with cancer.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	support embedded videos	3	0.38%
2	nonsmall cell lung	3	0.38%
3	doesnt support embedded	3	0.38%
4	browser doesnt support	3	0.38%
5	your browser doesnt	3	0.38%
6	a krasg12c mutation	3	0.38%
7	with a krasg12c	3	0.38%
8	nsclc with a	3	0.38%
9	cancer nsclc with	3	0.38%
10	cell lung cancer	3	0.38%
11	lung cancer nsclc	3	0.38%
12	advanced nonsmall cell	3	0.38%
13	as a targeted	3	0.38%
14	option for patients	3	0.38%
15	treatment option for	3	0.38%
16	krazati adagrasib as	3	0.38%
17	targeted treatment option	3	0.38%
18	a targeted treatment	3	0.38%
19	for patients with	3	0.38%
20	adagrasib as a	3	0.38%
21	p et al	2	0.26%
22	compliance stories about	2	0.26%
23	sorry your browser	2	0.26%
24	et al nature	2	0.26%
25	back overview kras	2	0.26%
26	and inclusion sponsorshipsgrants	2	0.26%
27	we convert possibility	2	0.26%
28	mirati we convert	2	0.26%
29	al mtap deletion	2	0.26%
30	convert possibility into	2	0.26%

#	Keyword	Frequency	Density
1	krazati adagrasib as a	3	0.37%
2	doesnt support embedded videos	3	0.37%
3	adagrasib as a targeted	3	0.37%
4	as a targeted treatment	3	0.37%
5	a targeted treatment option	3	0.37%
6	targeted treatment option for	3	0.37%
7	treatment option for patients	3	0.37%
8	option for patients with	3	0.37%
9	advanced nonsmall cell lung	3	0.37%
10	nonsmall cell lung cancer	3	0.37%
11	cell lung cancer nsclc	3	0.37%
12	cancer nsclc with a	3	0.37%
13	nsclc with a krasg12c	3	0.37%
14	with a krasg12c mutation	3	0.37%
15	lung cancer nsclc with	3	0.37%
16	browser doesnt support embedded	3	0.37%
17	your browser doesnt support	3	0.37%
18	stories lung cancer resources	2	0.25%
19	improve the lives of	2	0.25%
20	to improve the lives	2	0.25%
21	therapies to improve the	2	0.25%
22	targeted therapies to improve	2	0.25%
23	equity and inclusion sponsorshipsgrants	2	0.25%
24	diversity equity and inclusion	2	0.25%
25	request form email alerts	2	0.25%
26	form email alerts investor	2	0.25%
27	convert possibility into reality	2	0.25%
28	we convert possibility into	2	0.25%
29	mirati we convert possibility	2	0.25%
30	et al mtap deletion	2	0.25%
31	for the treatment of	2	0.25%
32	lung cancer resources medicines	2	0.25%
33	patient stories lung cancer	2	0.25%
34	email alerts investor contacts	2	0.25%
35	alerts investor contacts careers	2	0.25%
36	investor contacts careers contact	2	0.25%
37	contacts careers contact us	2	0.25%
38	sorry your browser doesnt	2	0.25%
39	2017236703713” campbell et al	1	0.12%
40	of 10000 patients nat	1	0.12%

#	URL	Whois	Check
1	https://www.facebook.com/MiratiTherapeutics/	Whois	facebook.com
2	https://twitter.com/Mirati	Whois	twitter.com
3	https://www.linkedin.com/company/mirati-therapeutics/	Whois	linkedin.com